4篇
您的检索式：作者名="Hiroyuki Yoshizumi"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding显示文摘 | Tetsuo Akimoto Hiroyuki Muramatsu Mitsuhiro Takahashi Jun-ichi Saito Yoshizumi Kitamoto Koichi Harashima Yasushi Miyazawa Masami Yamada Kazuto Ito Kouhei Kurokawa Hidetoshi Yamanaka Takashi Nakano Norio Mitsuhashi Hideo Niibe | 2004 | International Journal of Radiation Oncology Biology Physics2004，，4： | 1 |
| 2 | In Situ Dye Injection Bile Leakage Test of the Graft in Living Donor Liver Transplantation显示文摘 | Taketoshi Suehiro Mitsuo Shimada Keiji Kishikawa Tatsuo Shimura Yuji Soejima Tomoharu Yoshizumi Kohji Hashimoto Yasushi Mochida Yoshihiko Maehara Hiroyuki Kuwano | 2005 | Transplantation2005，，10： | 1 |
| 3 | Induced Order in Nonequivalent Two-Leg Hubbard Ladder显示文摘 | Hiroyuki Yoshizumi Takami Tohyama and Takao Morinari | | eprint0，，： | 1 |
| 4 | Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors显示文摘Background:Antiangiogenic tyrosine kinase inhibitors(TKIs)provide one of the few therapeutic options for effective treatment of hepatocellular carcinoma(HCC).However,patients with HCC often develop resistance toward antiangiogenic TKIs,and the underlying mechanisms are not understood.The aim of this study was to determine the mechanisms underlying antiangiogenic TKI resistance in HCC.Methods:We used an unbiased proteomic approach to define proteins that were responsible for the resistance to antiangiogenic TKIs in HCC patients.We evaluated the prognosis,therapeutic response,and serum insulin-like growth factor-binding protein-1(IGFBP-1)levels of 31 lenvatinib-treated HCC patients.Based on the array of results,a retrospective clinical study and preclinical experiments using mouse and human hepatoma cells were conducted.Additionally,in vivo genetic and pharmacological gain-and loss-of-function experiments were performed.Results:In the patient cohort,IGFBP-1 was identified as the signaling molecule with the highest expression that was inversely associated with overall survival.Mechanistically,antiangiogenic TKI treatment markedly elevated tumor IGFBP-1 levels via the hypoxia-hypoxia inducible factor signaling.IGFBP-1 stimulated angiogenesis through activation of the integrinα5β1-focal adhesion kinase pathway.Consequently,loss of IGFBP-1 and integrinα5β1 by genetic and pharmacological approaches re-sensitized HCC to lenvatinib treatment.Conclusions:Together,our data shed light onmechanisms underlying acquired resistance of HCC to antiangiogenic TKIs.Antiangiogenic TKIs induced an increase of tumor IGFBP-1,which promoted angiogenesis through activating the IGFBP-1-integrinα5β1 pathway.These data bolster the application of a new therapeutic concept by combining antiangiogenic TKIs with IGFBP-1 inhibitors. | Hiroyuki Suzuki Hideki Iwamoto Takahiro Seki Toru Nakamura Atsutaka Masuda Takahiko Sakaue Toshimitsu Tanaka Yasuko Imamura Takashi Niizeki Masahito Nakano Shigeo Shimose Tomotake Shirono Yu Noda Naoki Kamachi Miwa Sakai Kazutoyo Morita Masamichi Nakayama Tomoharu Yoshizumi Ryoko Kuromatsu Hirohisa Yano Yihai Cao Hironori Koga Takuji Torimura | 2023 | Cancer Communications2023，43，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员